 This is a non-randomized, open-label Phase 1b trial to establish the safety and recommended phase 2 dose RP2D of bavituximab in combination with pemetrexed and carboplatin in subjects with previously untreated stage IV non-squamous non-small cell lung cancer NSCLC. 